louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05313854: Diagnosis and Survival Prediction of Pancreatic Cancer by Machine Learning of Image Data
Official title: Diagnosis and Survival Prediction of Pancreatic Cancer by Machine Learning of Image Data
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pancreatic Cancer
Keywords: Pancreatic Cancer
Machine Learning
Radiomics
CT
MRI
Ultrasound
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2022-04-06
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: hospitalized patients with radiology conformed pancreatic tumor

Brief summary: This prospective cohort study is designed to investigate the diagnostic ability and prediction accuracy of pancreatic cancer by radiomics data and clinical data.

Detailed description: In this study, investigators aimed to investigate the diagnostic performance and prediction accuracy of pancreatic cancer by radiomics data and clinical data, which include CT scan, MRI, PET-CT, PET-MR, ultrasound, and clinical data.

Eligibility criteria: Inclusion Criteria:

Clinical diagnosis of pancreatic tumor; Must have CT / MRI / ultrasound data and pathology diagnosis

Exclusion Criteria:

Have other tumors along with pancreatic tumor; Clinical information missing

Primary outcomes:
measure: Patient overall survival
timeFrame: up to 3 years
Secondary outcomes:
measure: Pathology diagnosis
timeFrame: intraoperative
Other outcomes:
measure: Progression-free Survival
timeFrame: up to 3 years
Locations:
city: Shanghai
country: China
facility: Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Study officials:
affiliation: Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
name: Tao Chen, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06505954: LOWER URINARY TRACT SYMPTOMS
Official title: PREVALENCE OF LOWER URINARY TRACT SYMPTOMS AND CONTRIBUTING FACTORS AMONG MEDICAL STUDENTS
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Lower Urinary Tract Symptoms
Keywords: Lower Urinary Tract Symptoms
Medical students
Prevalence
Lead sponsor: University of Gaziantep
Sponsor class: OTHER
First posted: 2024-07-17
Enrollment: 278
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Medical students who have lower urinary tract symptoms are goal populations.

Brief summary: Lower urinary tract symptoms (LUTS) are observed in individuals with pathologies affecting the lower urinary system, such as detrusor overactivity, sphincter weakness, or sensory bladder disorder. LUTS can be categorized into storage, voiding, and post-micturition symptoms. Storage problems include increased frequency of urination, nocturia, urinary urgency, and incontinence. Voiding symptoms include decreased urine flow rate, hesitancy, and terminal dribbling, while post-micturition symptoms include post-micturition dribble and a sensation of incomplete bladder emptying. The prevalence of LUTS increases with age and is influenced by factors such as metabolic syndrome, gender, caffeine consumption habits, chronic psychological stress, bladder dysfunction, smoking, alcohol use, and constipation.

This study aims to investigate the prevalence of LUTS and contributing factors among medical students, a young population undergoing a stressful educational process.

A 43-question survey was prepared for all medical students from years 1 to 6. The survey included the Constipation Scoring System (CSS) to evaluate constipation, the Generalized Anxiety Disorder-7 (GAD-7) score to assess anxiety levels, and the Core Lower Urinary Tract Symptom Score (CLSS) to query LUTS. The survey also collected data on participants' dietary habits, smoking, alcohol and caffeine consumption, living conditions, age, gender, body mass index (BMI), and educational level. The study was approved by the local ethics committee of Gaziantep University (approval number 2024/234).


Eligibility criteria: Inclusion Criteria:

-All medical students from committee 1 to 6.

Exclusion Criteria:

* Participants who filled out the survey questions incompletely or incorrectly
* Participants who had additional diseases
* Participants who used medication for psychiatric or cardiac reasons
* Participants who had undergone surgery that could affect bladder function

Primary outcomes:
measure: Prevalence of lower urinary tract symptoms
timeFrame: Last six months
Secondary outcomes:
measure: Contributing factors
timeFrame: Last six months
Other outcomes:
Locations:
city: Gaziantep
country: Turkey
facility: Gaziantep University
state: Şehitkamil
Study officials:
affiliation: Gaziantep University Faculty of Medicine, Department of Urology
name: Muharrem Baturu
role: STUDY_CHAIR
References:
Clinical trial NCT02925754: Catastrophism Among Chronic Pain Patients in Rheumatology
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Catastrophizing Pain
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2016-10-06
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: adults hospitalized in the department of rheumatology of the Nîmes University Hospital with chronic pain (≥ 6 months)

Brief summary: Pain catastrophizing is conceptualized as a negative cognitive-affective response to anticipated or actual pain and has been associated with a number of important pain-related outcomes.

The aims of this study are

1. To describe the characteristics of the patients and determinants of catastrophizing in chronic painful patients hospitalized in rheumatology in the Nîmes University Hospital
2. To describe the impact of the catastrophizing on the level of insomnia and the drugs consumption in chronic painful patients hospitalized in rheumatology in the Nîmes University Hospital


Eligibility criteria: Inclusion Criteria:

* adults hospitalized in the department of rheumatology of the Nîmes University Hospital with chronic pain (≥ 6 months)

Exclusion Criteria:

* benzodiazepine or neuroleptic use for epilepsia, alcool, psychiatric disorders
* Restless Legs syndrom
* Obstructive Sleep Apnea
* narcolepsy

Primary outcomes:
measure: Pain Catastrophizing Scale
timeFrame: Day 0
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06906354: Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection
Official title: The Effect of Intrabronchial Therapy With Gentamycin and Dexamethason After Bronchoscopic Airway Clearance in Exacerbation of Bronchiectasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bronchiectasis Adult
Bronchiectasis With Acute Exacerbation
Keywords: bronchoscopy
bronchiectasis
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2025-04-02
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Fiberoptic Airway Clearance in Bronchiectasis Exacerbation and Gentamicin-Dexamethason Injection
Primary purpose: PREVENTION

Brief summary: Fiberoptic Bronchoscopic Removal of Secretions and Antibiotic Injection

Detailed description: fiberoptic bronchoscopic injection of dexamethason and gentamicin after airway clearance

Eligibility criteria: Inclusion Criteria:

1- Adult subjects. 2- Male and female subjects are enrolled. 3- patients with NCFB confirmed by chest high-resolution computed tomography (HRCT) 4- patients needing antibiotic treatment at the hospital due to exacerbation 5- Patients who underwent AC by bronchoscopy at the hospital.

-

Exclusion Criteria:

1- Uncooperative subjects. 2- Unwilling to participate. 3- Inability to lie on the back with raised arms over the head for HRCT. 4- Presence of cystic pulmonary fibrosis; 5- Patients with active pulmonary tuberculosis; 6- Those awaiting surgery; 7- Patients who underwent interventional therapy for hemoptysis; those with allergic bronchopulmonary aspergillosis (ABPA); 8- Patients who did not undergo bronchoscopy for different reasons or combined with lung cancer.

-

Primary outcomes:
measure: Dyspnea Borg Scale
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Chest Department -Faculty of Medicine
Study officials:
affiliation: Alexandria University
name: mohamed sabry Eltarhony, lecturer
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02023554: Drug Interaction Study of Azithromycin and Theophylline
Official title: A Pharmacokinetic Drug Interaction Study to Evaluate the Effect of Azithromycin on the Steady-State Plasma Levels of Theophylline in a Chinese Population
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Obstructive Pulmonary Disease
Asthma
Keywords: azithromycin
theophylline
CYP3A4
Lead sponsor: Zhujiang Hospital
Sponsor class: OTHER
First posted: 2013-12-30
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Macrolides are potent inhibitors of cytochrome P450 isoenzyme 3A4（CYP3A4）and thus interfere with the pharmacokinetics of many other drugs that are metabolised by this enzyme like theophylline.The aim of this study is to determine whether azithromycin can effect theophylline metabolism in patients.

Detailed description: In this non-blinded,auto-control study,patients with Chronic Obstructive Pulmonary Disease（COPD）or asthma will serve as their own controls during the 2-week treatment phase.The subjects will be co-administered oral doses of sustained release theophylline (100mg tablets,twice daily) and azithromycin (2x250mg capsules,once daily )in the first week.Then patients will received theophylline therapy alone with the same dose in the second week.Blood samples for the measurement of theophylline plasma concentrations will be collected on Days 8 and 15 prior to dosing.All adverse events whether elicited by query, spontaneously reported or observed by clinic staff will be evaluated by the investigator and reported in the subject's case report form.

Eligibility criteria: Inclusion Criteria:

* patients with COPD or asthma，aged 18-75 years;
* regularly visiting our hospital;
* meeting the indications for azithromycin and theophylline simultaneously;

Exclusion Criteria:

* patients with renal or hepatic dysfunction;
* patients with congestive heart failure;
* patients with hypothyroidism or hyperthyroidism;
* patients taking drugs likely to affect the theophylline metabolism in the preceding week;
* patients with severe chronic obstructive pulmonary disease,asthma or respiratory infection;

Primary outcomes:
measure: steady-state plasma concentration of theophylline
timeFrame: blood samples for theophylline will be collected on Days 8 and 15 before dosing
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Zhujiang Hospital,Southern Medical Universtiy
state: Guangdong
Study officials:
affiliation: Zhujiang Hospital,Southern Medical Unversity
name: Liqing Wang, Doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02314754: Outpatient Medical Abortion With Mifepristone and Misoprostol Through 77 Days of Gestation
Official title: Outpatient Medical Abortion With Mifepristone and Misoprostol Through 77 Days of Gestation: A Non-inferiority Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Medical Abortion
Lead sponsor: Gynuity Health Projects
Sponsor class: OTHER
First posted: 2014-12-11
Enrollment: 719
Sex: FEMALE
Minimum age (years): 11
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To demonstrate non-inferiority of the efficacy of 200 mg mifepristone followed in 24 to 48 hours by 800 µg buccal misoprostol in outpatient medical abortion services among women 71-77 days' compared to women 64-70 days' LMP.


Eligibility criteria: Inclusion Criteria:

* intrauterine pregnancy between 64 days and 77 days' LMP
* eligible for medical abortion according to study doctor assessment
* willing and able to sign consent form
* speak english or spanish (in US sites); speak the local language(s) (in international sites)
* agree to comply with the study procedures and visit schedule

Exclusion Criteria:

* Have known allergies or present other contraindications to mifepristone or misoprostol

Primary outcomes:
measure: Efficacy as determined by the proportion of successful terminations without surgical intervention (suction curettage or D&C) for any reason
timeFrame: 7-36 days
Secondary outcomes:
measure: Proportion of Individual Side Effects Experienced by Participants
timeFrame: 7-14 days
measure: Proportion of Women Who Determine Method Acceptable
timeFrame: 7-14 days
measure: Proportion of Providers Who Determine Method Acceptable
timeFrame: 7-36 days
Other outcomes:
Locations:
city: Hartford
country: United States
facility: Hartford GYN Center
state: Connecticut
city: Atlanta
country: United States
facility: Atlanta Women's Center
state: Georgia
city: Chicago
country: United States
facility: John H. Stroger, Jr. Hospital of Cook CountY
state: Illinois
city: Chicago
country: United States
facility: Family Planning Associates Medical Group
state: Illinois
city: Baku
country: Azerbaijan
facility: Scientific Research Institute of Obstetrics and Gynecology
city: Tbilisi
country: Georgia
facility: David Gagua Clinic
city: Mexico City
country: Mexico
facility: Clínica Comunitaria Santa Catarina
city: Ho Chi Minh City
country: Vietnam
facility: Hung Vuong Hospital
Study officials:
affiliation: Gynuity Health Projects
name: Beverly Winikoff, MD,MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03570554: A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale
Official title: A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Osteoarthritis, Knee
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2018-06-27
Enrollment: 41
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Osteoarthritis is a common, chronic, progressive, skeletal, degenerative disorder that frequently affects several joints such as knee, hip, spine and hands.This placebo-controlled clinical trial assessed the effects of naproxen sodium, acetaminophen and celecoxib on stiffness in subjects with osteoarthritis.

Detailed description: The primary objective of the study was to assess the responsiveness of the Brief Arthritis Stiffness Scale (BASS) for detecting treatment effects of common over-the-counter (OTC) analgesics and a common prescription analgesic in subjects with knee osteoarthritis.

Eligibility criteria: Inclusion Criteria:

* Age between 40 and 80 years
* Body Mass Index (BMI) between 18 and \<40 kg/m\^2
* Unilateral or bilateral osteoarthritis of the knee
* Diagnostic quality radiography of the target knee performed no more than 1 year prior to baseline showing evidence of osteoarthritis (OA) with Kellgren and Lawrence grade of II or III
* Joint Stiffness Severity score ≥3.0 on a 0-10 numerical rating scale (NRS) at screening

Exclusion Criteria:

* History of underlying inflammatory arthropathy, rheumatoid arthritis or fibromyalgia
* History of or scheduled for target knee replacement surgery
* Recent injury in target knee (past 4 months)

Primary outcomes:
measure: Sum of Change in Brief Arthritis Stiffness Scale (BASS) Scores Over the 4-day Treatment Period
timeFrame: 4 days
Secondary outcomes:
measure: Absolute Brief Arthritis Stiffness Scale (BASS) Score at Each Time Point
timeFrame: 4 days
measure: Change From Baseline in Brief Arthritis Stiffness Scale (BASS) Score at Day 4
timeFrame: Day 4
Other outcomes:
Locations:
city: Chandler
country: United States
facility: Radiant Research, Inc.
state: Arizona
city: Pinellas Park
country: United States
facility: Radiant Research, Inc.
state: Florida
city: Chicago
country: United States
facility: Radiant Research, Inc.
state: Illinois
city: Cincinnati
country: United States
facility: Radiant Research, Inc.
state: Ohio
city: San Antonio
country: United States
facility: Radiant Research, Inc.
state: Texas
Study officials:
References:
Clinical trial NCT01196754: Pharmacokinetic of Sevoflurane During a 48h Sedation in Intensive Care Unit With AnaConDa®
Official title: Pharmacokinetic of Sevoflurane During a 48h Sedation in ICU With AnaConDa®
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sedation
Keywords: Pharmacokinetics
Sevoflurane
Fluorides
Sedation
Adult patients with a predicted sedation more than 48 h
Stable respiratory and hemodynamic conditions for SBT
Consent of patients
Arterial line
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
Collaborators: name: University Hospital, Estaing
First posted: 2010-09-08
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: SCREENING

Brief summary: This is a prospective clinical monocentric study in ICU with sedated ventilated patients with sevoflurane during 48 h with the AnaConda® system, establishing pharmacokinetic model of sevoflurane.

Detailed description: Prospective clinical monocentric study in ICU with sedated ventilated patients with sevoflurane during 48 h with the AnaConda® system, establishing pharmacokinetic model of sévoflurane and its metabolites (hydroxyfluroisopropanol, fluoride)

Eligibility criteria: Inclusion Criteria:

* Adult patients ventilated more than 48 h
* Stable respiratory and hemodynamic conditions
* Consent of patients or family
* Arterial line

Exclusion Criteria:

* Acute kidney injury
* Obesity
* Sevoflurane anaphylaxia

Primary outcomes:
measure: Determination of plasmatic concentrations of sévoflurane at different times of a 48h sedation of sévoflurane.
timeFrame: during 48 hours
Secondary outcomes:
measure: Determination of plasmatic concentrations of HFIP and fluoride at different times of a 48h sedation of sévoflurane. Determination of a pharmacokinetic model of sévoflurane.
timeFrame: during 48 hours
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: CHU Clermont-Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Daniel Bourdeaux
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01031654: Marital Functioning Among Combat Veterans
Official title: Marital Functioning Among Combat Veterans
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Stress Disorders, Post-Traumatic
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2009-12-14
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: A total of 10 couples (N=20) will be enrolled in the study. At least one of the marital dyad will be an Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) veteran.

Brief summary: The purpose of this research study is to examine marital dynamics related to husband-wife reunification following the veteran's return

Detailed description: We are interested in patterns of husband/wife communication and interaction regarding conflict resolution, trauma experiences, marital satisfaction, occupational functioning, social functioning, family functioning, and substance use.

We hope to discover ways to assist couples in reducing marital stress.

Eligibility criteria: Inclusion Criteria:

* 18 and older
* Married or in a married like relationship
* One partner has served in Afghanistan or Iraq

Exclusion Criteria:

* Separated

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Cheryl Gore-Felton Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01260454: The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain
Official title: The Qutenza® Patch for Disabling Treprostinil Infusion Site Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Pulmonary Hypertension
Pulmonary Arterial Hypertension
Keywords: Qutenza
Capsaicin
Remodulin
Treprostinil
Lead sponsor: University of Rochester
Sponsor class: OTHER
Collaborators: name: United Therapeutics
First posted: 2010-12-15
Enrollment: 6
Sex: ALL
Minimum age (years): 15
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Subcutaneous treprostinil (Remodulin) is effective therapy for pulmonary arterial hypertension, a life threatening disease of the lung blood vessels. Unfortunately, treprostinil is irritating to the skin and many patients experience intense pain at the infusion site for the first 7-10 days after placing a new subcutaneous infusion site.

Qutenza is an FDA approved formulation of 8% capsaicin that is approved for the treatment of post-herpetic neuralgia, a painful skin condition. The investigators hypothesize that pretreatment of an area of skin with Qutenza would decrease the pain associated with a new treprostinil infusion site. The investigators hope that Qutenza will decrease both the intensity of the pain and the duration of the pain after patients place a new treprostinil infusion site.

In this initial study, the investigators will provide Qutenza in open-label, unblinded fashion and ask patients to rate their pain using a diary tool with which they are already comfortable.


Eligibility criteria: Inclusion Criteria:

* Pulmonary Hypertension
* Using subcutaneous treprostinil
* Already participating as a subject in our prospective study of infusion site pain
* Has documented debilitating pain (6/10 or greater) in the study after a site change

Exclusion Criteria:

* Uncontrolled hypertension
* Recent stroke or myocardial infarction

Primary outcomes:
measure: Pain Score on a Visual Analogue Scale
timeFrame: 14 days after a new infusion site
Secondary outcomes:
measure: Number of Participants Who Experienced Greater Than 6 Pain Level Using the 10 Point Visual Analog Score
timeFrame: 60 minute period of patch application and subsequent 3 days
measure: Number of Participants Who Used of Narcotics Following a Treprostinil Infusion Site Change
timeFrame: 14 days
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mary M. Parkes Asthma Center, University of Rochester
state: New York
Study officials:
affiliation: University of Rochester
name: R James White, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: